REALM China Extension Study

Nanfang Hospital, Southern Medical University

Status: Unknown

Conditions: Hepatitis B, Chronic

Treatments: Other: follow-up

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT02974829

AI463520

Details and patient eligibility

About

The purpose of this study is to conduct an investigator initiated observational study to continue to follow up the China subset of study participants for another 5 years after they complete participation in the REALM Study

Enrollment: 4,000 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients completed REALM Study in China
2. Patients willing to sign the consent to continue anti-viral treatment or post-treatment follow up, and agree his/her legacy data and blood/liver histology samples collected in REALM Study may be used for the analyses planned for this new study.

Exclusion criteria

1. Patients who do not provide consent to participate in this study;
2. Patients are formally enrolled into any investigational drug clinical trial after the REALM study.

Trial design

4,000 participants in 1 patient group

All patients

Description:

Continuing with marketed anti-HBV or off-treatment in real-life setting

Treatment:

Other: follow-up